Open AccessA Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer
Author(s) -
Ramesh K. Ramanathan,
Gary W. Thomas,
Alok A. Khorana,
Satish Shah,
Cathy Zhou,
S. S. Wong,
George W. Cole,
Danelle F. James,
Nashat Gabrail
Publication year - 2019
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000495988
Subject(s) - gemcitabine , medicine , conventional pci , pancreatic cancer , oncology , cancer , gastroenterology , myocardial infarction
Tissue factor overexpression is associated with tumor progression, venous thromboembolism, and worsened survival in patients with cancer. Tissue factor and activated factor VII (FVIIa) complex may contribute to tumor invasiveness by promoting cell migration and angiogenesis. The study objective was to evaluate safety, pharmacokinetics, and efficacy of PCI-27483, a selective FVIIa inhibitor.